OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vokes on Moving Immunotherapy into Frontline for Head and Neck Cancer

January 6th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the possibility of moving immunotherapy agents into the frontline setting for patients with head and neck cancer.

Dr. Husain on Monitoring the Emergence of T790M in Lung Cancer

January 6th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR-mutated NSCLC.

Dr. Oh on the Safety Profile of Docetaxel in Prostate Cancer

January 6th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the safety profile of docetaxel when administered to patients with prostate cancer.

Dr. Blok on Results of Adjuvant Letrozole Study in Breast Cancer

January 6th 2017

Erik J. Blok, MD, Department of Medical Oncology at Leiden University Medical Center, discusses the duration of adjuvant endocrine therapy. Blok claims that there is no breast cancer survival benefit in extending adjuvant letrozole treatment from 2.5 to 5 years.

Dr. Odisho on a Risk Prediction Model in Renal Cell Carcinoma

January 6th 2017

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

Cecile Pizot on Breast Cancer Mortality in Latin America and Asia

January 6th 2017

Cecile Pizot, biostatistician in epidemiology at the International Prevention Research Institute, discusses the changes in mortality rates in breast cancer around the world. In a study on 47 countries, 39 saw breast cancer mortality rates decline, but mortality rates were on the rise in Latin American and Asian countries.

Dr. Mittendorf on Vaccines as Prevention for Breast Cancer

January 6th 2017

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the possibility of using vaccines as a preventative measure for breast cancer, particularly to fight recurrence.

Dr. Marshall on Y-90 Mechanism of Action in Liver-Dominant CRC

January 5th 2017

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the mechanism of action of Yttrium-90 in the treatment of patients with liver-dominant, metastatic colorectal cancer.

Dr. Markman on the Search for Actionable Biomarkers in Ovarian Cancer

January 5th 2017

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the search for actionable biomarkers in the treatment of patients with ovarian cancer.

Dr. Birrer on Challenges With Patient Demographics in Cervical Cancer

January 5th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Dr. Kolibaba on Efficacy of Entospletinib in Mantle Cell Lymphoma

January 4th 2017

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses why the Syk inhibitor entospletinib demonstrates efficacy in patients with mantle cell lymphoma (MCL).

Dr. Carbone on Effectiveness of Different Lung Cancer Therapies

January 4th 2017

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer

January 4th 2017

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC

January 4th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Dr. Zelenetz on Treatment for Patients With CLL Who Fail on Ibrutinib or Idelalisib

January 4th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia who fail on ibrutinib or idelalisib.

Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer

January 4th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia

December 31st 2016

Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.

Dr. Puzanov on Management of Adverse Events in Melanoma

December 30th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

Dr. Goy on Bortezomib in MCL Treatment

December 30th 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.

Dr. Hamid on Patient Selection for Immunotherapy Regimens in Melanoma

December 30th 2016

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.